2024
Seroprevalence of Treponema pallidum infection among high-risk populations from Brazil
Queiroz J, Barbosa M, Perez E, da Silva B, de Souza G, Gonçalves C, Croda J, Simionatto S. Seroprevalence of Treponema pallidum infection among high-risk populations from Brazil. Acta Tropica 2024, 256: 107255. PMID: 38761835, DOI: 10.1016/j.actatropica.2024.107255.Peer-Reviewed Original ResearchConceptsSexually transmitted infectionsHigh-risk groupCases of syphilisFactors associated with syphilisPregnant womenHistory of sexually transmitted infectionsPublic health strategiesHealthy populationSignificant public health concernPrevent future complicationsHigh risk of infectionHigh-risk populationPublic health concernHealth strategiesParticipant demographicsCross-sectional oneRisk of infectionVulnerable populationsFuture complicationsPLHIVTreatment outcomesHealth concernHigh riskSyphilisInfection
2022
Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis
Lind M, Robertson A, Silva J, Warner F, Coppi A, Price N, Duckwall C, Sosensky P, Di Giuseppe E, Borg R, Fofana M, Ranzani O, Dean N, Andrews J, Croda J, Iwasaki A, Cummings D, Ko A, Hitchings M, Schulz W. Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis. PLOS Medicine 2022, 19: e1004136. PMID: 36454733, PMCID: PMC9714718, DOI: 10.1371/journal.pmed.1004136.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionBooster vaccinationPrior infectionOmicron infectionPrimary vaccinationMRNA vaccinationOdds ratioAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionPrior SARS-CoV-2 infectionTest-negative case-control analysisYale New Haven Health SystemTest-negative case-control studyCOVID-19 mRNA vaccinationSyndrome coronavirus 2 infectionOmicron variant infectionPrior infection statusCoronavirus 2 infectionCase-control studyCase-control analysisOdds of infectionRisk of infectionRace/ethnicityBooster dosesDate of test